泰林生物
(300813)
| 流通市值：15.19亿 | | | 总市值：24.20亿 |
| 流通股本：7605.11万 | | | 总股本：1.21亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 210,343,842.89 | 264,872,528.62 | 171,228,615.53 | 300,037,604.18 |
| 应收票据及应收账款 | 44,473,461.2 | 43,546,552.81 | 43,636,934.99 | 44,912,332.1 |
| 应收账款 | 44,473,461.2 | 43,546,552.81 | 43,636,934.99 | 44,912,332.1 |
| 应收款项融资 | 9,209,827.65 | 9,837,937.21 | 22,347,340.06 | 12,474,326.71 |
| 预付款项 | 3,095,868.41 | 3,779,076.27 | 7,536,756.56 | 4,308,405.53 |
| 其他应收款合计 | 10,046,756.44 | 8,485,615.12 | 12,433,173.1 | 11,453,251.12 |
| 存货 | 141,018,169.49 | 144,134,014.09 | 159,406,248.73 | 158,909,437.83 |
| 合同资产 | 9,390,390 | 9,008,033.49 | 8,248,750.54 | 6,523,664.04 |
| 其他流动资产 | 187,295,324.75 | 149,098,120.91 | 211,484,038.07 | 78,787,124.03 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 614,873,640.83 | 632,761,878.52 | 636,321,857.58 | 617,406,145.54 |
| 非流动资产: | | | | |
| 长期股权投资 | 8,141,620.34 | 8,144,676.28 | 8,000,000 | 8,000,000 |
| 投资性房地产 | 8,699,475.37 | 8,774,709.79 | 10,052,324.06 | 10,139,846.24 |
| 固定资产 | 256,294,198.81 | 260,054,131.14 | 258,669,490.39 | 262,740,230.62 |
| 在建工程 | 8,012,272.07 | 6,656,387.04 | 5,838,339.74 | 4,312,333.37 |
| 无形资产 | 10,803,786.73 | 10,918,106.68 | 11,037,386 | 10,998,081.4 |
| 长期待摊费用 | 30,859,847.88 | 31,246,676.91 | 31,656,228.25 | 32,429,566.18 |
| 递延所得税资产 | 87,781.81 | 87,781.81 | 5,148.15 | 11,554.22 |
| 其他非流动资产 | 1,246,700 | 1,263,579.9 | 508,300 | 3,607,711 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 324,145,683.01 | 327,146,049.55 | 325,767,216.59 | 332,239,323.03 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 939,019,323.84 | 959,907,928.07 | 962,089,074.17 | 949,645,468.57 |
| 流动负债: | | | | |
| 短期借款 | - | 3,669,656.41 | 15,645,426.7 | 8,250,155.45 |
| 应付票据及应付账款 | 13,497,537.39 | 15,194,299.97 | 16,479,055.41 | 15,430,950.9 |
| 应付账款 | 13,497,537.39 | 15,194,299.97 | 16,479,055.41 | 15,430,950.9 |
| 合同负债 | 74,197,818.99 | 76,580,599.71 | 84,965,135.53 | 85,633,822.94 |
| 应付职工薪酬 | 11,533,202.18 | 26,117,973.72 | 11,884,343.49 | 12,287,099.98 |
| 应交税费 | 2,243,880.71 | 4,578,096.22 | 3,824,019.21 | 2,222,687.86 |
| 其他应付款合计 | 7,527,023.86 | 6,235,446.87 | 6,173,774.26 | 7,510,526.68 |
| 其他流动负债 | 3,048,077.18 | 3,409,029.76 | 2,299,959.13 | 4,230,196.05 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 112,047,540.31 | 135,785,102.66 | 141,271,713.73 | 135,565,439.86 |
| 非流动负债: | | | | |
| 应付债券 | - | - | 161,581,781.72 | 159,619,546.57 |
| 递延所得税负债 | 3,393,283.59 | 3,393,283.59 | 3,630,938.23 | 3,630,938.23 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 3,393,283.59 | 3,393,283.59 | 165,212,719.95 | 163,250,484.8 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 115,440,823.9 | 139,178,386.25 | 306,484,433.68 | 298,815,924.66 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 121,199,219 | 121,199,219 | 109,142,103 | 109,138,939 |
| 其他权益工具 | - | - | 67,271,538.3 | 67,288,949.93 |
| 资本公积 | 420,507,953.91 | 420,507,953.91 | 201,822,362.86 | 201,766,734.15 |
| 盈余公积 | 27,628,568.73 | 27,628,568.73 | 27,628,568.73 | 27,628,568.73 |
| 未分配利润 | 254,242,758.3 | 250,714,603.67 | 248,978,604.64 | 244,245,982.92 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 823,578,499.94 | 820,050,345.31 | 654,843,177.53 | 650,069,174.73 |
| 少数股东权益 | - | 679,196.51 | 761,462.96 | 760,369.18 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 823,578,499.94 | 820,729,541.82 | 655,604,640.49 | 650,829,543.91 |
| 负债和股东权益合计 | 939,019,323.84 | 959,907,928.07 | 962,089,074.17 | 949,645,468.57 |
| 公告日期 | 2025-04-28 | 2025-04-28 | 2024-10-30 | 2024-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |